{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T23:27:06Z","timestamp":1748906826306},"reference-count":33,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"vor","delay-in-days":821,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2001,4]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Emergence of antibiotic resistant <jats:italic>Helicobacter pylori<\/jats:italic> has necessitated the identification of alternate therapies for the treatment of this infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>To assess the <jats:italic>in vitro<\/jats:italic> efficacy of two investigational agents: DMG\u2010MINO CL 344 (a N,N\u2010dimethylglycylamido derivative of minocycline), and davercin, a cyclic carbonate of erythromycin A as compared to older antibiotics (clarithromcyin, azithromycin, minocycline, tetracycline, ofloxacin, ciprofloxacin, cefixime) against clinical isolates of <jats:italic>H. pylori<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Testing was performed using the agar dilution method approved by the NCCLS subcommittee on antimicrobial susceptibility testing, <jats:italic>Helicobacter pylori<\/jats:italic> working group. Under these guidelines, Mueller\u2013Hinton agar containing 5% aged sheep blood was used. All incubations were done under CampyPak Plus conditions for 72\u2003h at 37\u2003\u00b0C. The drug concentrations in the agar ranged from 0.016 to 16\u2003\u03bcg\/mL. Twenty\u2010one clarithromycin\u2010resistant and 16 clarithromycin\u2010susceptible clinical isolates of <jats:italic>H. pylori<\/jats:italic> obtained from patients with duodenal ulcer were used. <jats:italic>H. pylori<\/jats:italic> ATCC 43504 was used as the control in all determinations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Against clarithromycin susceptible isolates, all antimicrobial agents except the fluoroquinolones were highly effective. Against clarithromycin\u2010resistant <jats:italic>H. pylori<\/jats:italic>, the MIC<jats:sub>50<\/jats:sub>\/MIC<jats:sub>90<\/jats:sub> values showed that the tetracyclines and cefixime were the most efficacious agents. The fluoroquinolones and macrolides were ineffective. Macrolide cross\u2010resistance was detected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Macrolide cross\u2010resistance prevents the use of this entire class of antimicrobials when clarithromycin resistance is present. Tetracyclines and cefixime are possible alternative agents for the treatment of <jats:italic>H. pylori<\/jats:italic> infection in these patients.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2001.00957.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:44:03Z","timestamp":1047354243000},"page":"487-492","source":"Crossref","is-referenced-by-count":17,"title":["Comparative efficacy of new investigational agents against <i>Helicobacter pylori<\/i>"],"prefix":"10.1111","volume":"15","author":[{"given":"M. S.","family":"Osato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. G.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. A.","family":"Piergies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. J.","family":"Bochenek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. T.","family":"Testa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Y.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0732-8893(99)00038-3"},{"key":"e_1_2_6_3_2","first-page":"357","article-title":"Antimicrobial resistance in Helicobacter pylori: a global overview","volume":"61","author":"Glupczynski Y","year":"1998","journal-title":"Acta Gastroenterol Belg"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199908002-00007"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0924-8579(99)00079-5"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199651040-00002"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.11.2747"},{"key":"e_1_2_6_8_2","first-page":"81","article-title":"[Antibiotic\u2010resistant H. pylori strains in the last ten years in Japan]","volume":"57","author":"Murakami K","year":"1999","journal-title":"Nippon Rinsho"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1996.23164000.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.11.2270"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.11.2628"},{"key":"e_1_2_6_12_2","first-page":"213","article-title":"Comparison of the mechanism of action of cyclic 11,12\u2010erythromycin A carbonate and erythromycin A","volume":"27","author":"Klita S","year":"1980","journal-title":"Acta Biochim Pol"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.43.566"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.4.738"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.10.2513"},{"key":"e_1_2_6_16_2","unstructured":"National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing VIth Informational Supplement M100S9 1999. National Committee for Clinical Laboratory Standards Villanova PA 1999."},{"key":"e_1_2_6_17_2","unstructured":"UtrupLJ FlammR OsatoM et\u2003al. Susceptibility testing standardization and quality control ranges forHelicobacter pylori. American Society for Microbiology 1998: 98th General Meeting C\u201031 1998."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00350.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70100-3"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00009.x"},{"key":"e_1_2_6_21_2","first-page":"484","article-title":"[Anaerobic microbes in perimandibular inflammation]","volume":"85","author":"Danielewiczowa K","year":"1984","journal-title":"Rev Stomatol Chir Maxillofac"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.2.477"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.2.283"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/37.3.473"},{"key":"e_1_2_6_25_2","first-page":"544","article-title":"[In vitro activity of 16 antimicrobial agents against Helicobacter (Campylobacter) pylori]","volume":"7","author":"Garcia\u2010Rodriguez JA","year":"1989","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1993.tb00083.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.5.1133"},{"key":"e_1_2_6_28_2","first-page":"261","article-title":"Antimicrobial susceptibility pattern and biotyping of Helicobacter pylori isolates from patients with peptic ulcer diseases","volume":"102","author":"Sharma S","year":"1995","journal-title":"Indian J Med Res"},{"key":"e_1_2_6_29_2","first-page":"281","article-title":"[Drug susceptibility of clinically isolated Helicobacter pylori]","volume":"51","author":"Nakae M","year":"1998","journal-title":"Jpn J Antibiot"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.12.2426"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.31.9.973"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01964274"},{"key":"e_1_2_6_33_2","unstructured":"OsatoMS ReddyR ReddySG PenlandRL GrahamDY.Primary metronidazole and clarithromycin resistance ofHelicobacter pyloriisolated from clinical trials in the United States between 1993 and 1999: Effect of patient demographics and test methodology.Arch Intern Med1993; in press."},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.164_b.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.00957.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.00957.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2001.00957.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T01:33:11Z","timestamp":1697506391000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2001.00957.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,4]]}},"alternative-id":["10.1046\/j.1365-2036.2001.00957.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2001.00957.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,4]]}}}